Industrial Sonomechanics Publishes Groundbreaking Pharmacokinetic Study of Two Delta-8 THC Nanoemulsions
MIAMI, April 9, 2024 /PRNewswire/ -- Industrial Sonomechanics® (ISM) has recently completed a groundbreaking pre-clinical pharmacokinetic study, comparing two orally administered Delta-8 THC nanoemulsions (liquid and powdered) with a Delta-8 THC solution in MCT oil. The results demonstrate considerable advantages of nanoemulsions produced with ISM's ultrasonic equipment and NanoStabilizers®, and are detailed in a recent publication. This marks the industry's first pre-clinical study of Delta-8 THC nanoemulsions.
Study Aims and Design:
For years, ISM's ultrasonic equipment and NanoStabilizers® have enabled companies around the world to produce their own water-soluble liquid and powdered nano-formulations that are infused into beverages, edibles, and tablets, and significantly improve absorption profiles of the incorporated bioactive ingredients.
The main pharmacokinetic parameter of interest for most bioactives (cannabinoids, alkaloids, terpenes, etc.) is the rate of absorption into the bloodstream, characterized as the "onset time", "time to maximum bloodstream concentration", and/or "average bloodstream concentration over a time window of interest".
This study was aimed at evaluating the rate of oral absorption of Delta-8 THC formulated as two nanoemulsions: translucent liquid (made with NanoStabilizer®-LT) and powdered (made with NanoStabilizer®-LSO), and as an MCT oil solution. The study parameters were optimized for the rate of absorption evaluation, rather than other, less consequential parameters (absolute bioavailability, food effects, etc.).
Results: Nanoemulsions Very Significantly Outperform MCT Oil Solution
During the most important first hour after administration, NanoStabilizer®-LT and -LSO-based nanoemulsions provided 15.6x and 18.8x greater absorption of Delta-8 THC, respectively, than the MCT oil solution.
During the extended 4-hour period after administration, NanoStabilizer®-LT and -LSO-based nanoemulsions provided 4.1x and 3.4x greater absorption of Delta-8 THC, respectively, than the MCT oil solution.
Both nanoemulsions enabled a much more rapid onset time and a much shorter time to maximum bloodstreamconcentration (~5 min and <1 hour, respectively) than the MCT oil solution (~1 hour and 6 hours, respectively).
Translucent liquid and powderedDelta-8 THC nanoemulsions displayed similar pharmacokinetic profiles.
Conclusions:
Delta-8 THC nanoemulsions made with ISM's technology provide an almost immediate onset time and considerably greater absorption within time windows of interest.
ISM's nanoemulsions of bioactives (cannabinoids, alkaloids, terpenes, etc.) are potentially advantageous for creating fast-acting infused products, such as beverages, edibles, water-soluble powder mixes, tablets, and many others.
ISM is a U.S.-based R&D, equipment design & manufacturing, and process consulting firm specializing in high-intensity ultrasonic technology for the production of nano-formulations.
BetterLife Pharma Inc. ("BetterLife" or the "Company") , an emerging biotech company focused on the development and commercialization of non-hallucinogenic LSD-based therapeutics for mental disorders, today announced that the Company intends to...
Celonis, the global leader in Process Mining, today announced it has appointed Mark Jacobs to the role of Senior Vice President North America Sales. As the Go-to-Market leader for North America, Jacobs will work closely with new and existing...
DXC Technology , a leading Fortune 500 global technology services company, today announced it will participate in the following investor conferences:
J.P. Morgan's Technology, Media, & Telecom 2024 Conference ? Raul Fernandez, President and CEO, is...
Intercontinental Exchange, Inc. ("ICE") announced today that it is commencing a private exchange offer (the "Exchange Offer") with respect to the outstanding 3.625% Senior Notes due 2028 (the "BK Notes") issued by Black Knight InfoServ, LLC, a...
Spyre Therapeutics, Inc. (the "Company" or "Spyre"), a development-stage biotechnology company advancing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches for the treatment of Inflammatory Bowel...